SIGN UP
LOG IN
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga·04/07/2025 12:08:52
Listen to the news
Gainers
- Bluejay Diagnostics (NASDAQ:BJDX) stock increased by 165.7% to $9.38 during Monday's pre-market session. The company's market cap stands at $5.1 million.
- Gyre Therapeutics (NASDAQ:GYRE) stock increased by 37.28% to $9.5. The market value of their outstanding shares is at $889.3 million.
- Tharimmune (NASDAQ:THAR) shares moved upwards by 35.31% to $1.59. The market value of their outstanding shares is at $3.0 million.
- Molecular Partners (NASDAQ:MOLN) stock rose 26.07% to $4.5. The market value of their outstanding shares is at $165.9 million.
- Cue Biopharma (NASDAQ:CUE) stock moved upwards by 19.98% to $0.81. The company's market cap stands at $51.3 million.
- I-MAB (NASDAQ:IMAB) shares increased by 18.63% to $0.81. The company's market cap stands at $65.2 million. As per the press release, FY earnings came out 2 days ago.
Losers
- Quoin Pharmaceuticals (NASDAQ:QNRX) stock fell 37.0% to $0.15 during Monday's pre-market session. The company's market cap stands at $3.0 million.
- CeriBell (NASDAQ:CBLL) shares decreased by 29.45% to $13.01. The market value of their outstanding shares is at $466.6 million.
- Bioventus (NASDAQ:BVS) stock declined by 22.45% to $6.46. The company's market cap stands at $422.2 million.
- Kewaunee Scientific (NASDAQ:KEQU) shares decreased by 21.48% to $28.01. The market value of their outstanding shares is at $79.9 million.
- Protagenic Therapeutics (NASDAQ:PTIX) stock declined by 20.64% to $0.31. The company's market cap stands at $2.2 million.
- Connect Biopharma Hldgs (NASDAQ:CNTB) stock fell 20.64% to $0.5. The company's market cap stands at $27.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.